Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors

NCT00104117 is registered in ClinicalTrials.gov with Symphony Evolution, Inc. as lead sponsor.

NCT NCT00104117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors
Lead sponsor
Symphony Evolution, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2004
Completion date
October 31, 2008
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer